The dynamics of HER2 status in esophageal adenocarcinoma

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K.J., Stap, Lisanne, Jibodh-Mulder, Rajni A., Gisbertz, Susanne S., van Berge Henegouwen, Mark I., van Montfoort, Maurits L., Hulshof, Maarten C.C.M., Krishnadath, Kausilia K., van Oijen, Martijn G.H., Bijlsma, Maarten F., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2018
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://ncbi.nlm.nih.gov/pubmed/29928485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25507
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料